CME in Minutes: Education in Cardiology & Pulmonology - Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

01/02/25 • 13 min

CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.

Previous Episode

undefined - David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

Next Episode

Jai Radhakrishnan, MD, MS - IgA Nephropathy in Focus: Novel Treatment Strategies for Nephrologists and PCPs

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.